Efgartigimod for Thyroid Eye Disease
(UplighTED Trial)
Trial Summary
What is the purpose of this trial?
This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up observational period while off study drug. Some participants may also enter the open-label treatment period with efgartigimod PH20 SC. The study duration varies from approximately 60 to 110 weeks. An alternative list of clinical sites open for recruitment could be found in the other UplighTED study record (https://www.clinicaltrials.gov/study/NCT06307613)
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications, but it mentions that the use of some medications before screening is an exclusion criterion. It's best to discuss your current medications with the trial team to see if they affect your eligibility.
How does the drug Efgartigimod PH20 SC differ from other treatments for thyroid eye disease?
Efgartigimod PH20 SC is unique because it targets the immune system by reducing the levels of specific antibodies that contribute to thyroid eye disease, offering a novel approach compared to existing treatments like teprotumumab, which targets a different receptor involved in the disease process.12345
Eligibility Criteria
Adults with active, moderate-to-severe thyroid eye disease (TED) who've had symptoms start within the last year can join. They must be over 18, able to consent and follow the study plan, have their thyroid condition under control or only mildly off balance. Participants need to use birth control and women must test negative for pregnancy.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Double-Blinded Treatment Period
Participants receive efgartigimod PH20 SC or placebo PH20 SC in a double-blinded manner
Follow-up Observational Period
Participants are monitored for safety and effectiveness after treatment while off study drug
Open-label Treatment Period
Participants may opt into continuation of treatment with efgartigimod PH20 SC
Treatment Details
Interventions
- Efgartigimod PH20 SC (Monoclonal Antibodies)
Efgartigimod PH20 SC is already approved in European Union, United States, Japan, China for the following indications:
- Generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive
- Generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive
- Generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive